World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
125
Citations
50104
World Ranking
289
National Ranking
186

Medicine

D-Index
125
Citations
50150
World Ranking
3127
National Ranking
1729

Research.com Recognitions

  • 2020 - Member of the National Academy of Sciences

Overview

John T. Schiller is affiliated with the National Institutes of Health in the United States and has contributed extensively to the field of medicine, focusing primarily on epidemiology, immunology, oncology, surgery, and molecular biology. Their research spans over 100 publications, with a notable emphasis on cervical cancer and HPV research, hepatitis B virus studies, and immunotherapy and immune responses.

The main topics of work covered by their research include:

  • Cervical Cancer and HPV Research
  • Hepatitis B Virus Studies
  • Immunotherapy and Immune Responses
  • Genital Health and Disease
  • Virus-based Gene Therapy Research
  • Herpesvirus Infections and Treatments
  • Molecular Biology Techniques and Applications

Schiller's frequent co-authors include Douglas R. Lowy, Carolina Porras, Aimée R. Kreimer, Rolando Herrero, and Allan Hildesheim. These collaborations have contributed to a significant body of work, often published in high-impact scientific venues.

The scientist's most frequent publication outlets encompass:

  • Vaccine
  • JNCI Journal of the National Cancer Institute
  • npj Vaccines
  • Cancer Research
  • The Journal of Infectious Diseases

Recent notable papers authored or co-authored by John T. Schiller include:

  • "Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial" (2020), published in JNCI Journal of the National Cancer Institute
  • "Human Papillomavirus Vaccines" (2021), published in The Journal of Infectious Diseases
  • "An Introduction to Virus Infections and Human Cancer" (2020), published in Recent Results in Cancer Research
  • "Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial" (2020), published in The Lancet Oncology
  • "Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial" (2020), published in JNCI Journal of the National Cancer Institute

In recognition of their contributions to science, John T. Schiller was named a Member of the National Academy of Sciences in 2020.

Best Publications

  • Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

    R Kirnbauer;F Booy;N Cheng;D R Lowy

  • HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.

    P. Hawley-Nelson;K.H. Vousden;N.L. Hubbert;D.R. Lowy

  • Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck

    Mork J;Lie Ak;Glattre E;Hallmans G

  • A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

    John T. Schiller;Xavier Castellsagué;Suzanne M. Garland

  • Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.

    Reinhard Kirnbauer;Janet Taub;Heather Greenstone;Richard Roden

  • Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

    Allan Hildesheim;Rolando Herrero;Sholom Wacholder;Ana C. Rodriguez

  • Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine

    Clayton D. Harro;Yuk Ying Susana Pang;Richard B.S. Roden;Allan Hildesheim

  • Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

    F Breitburd;R Kirnbauer;N L Hubbert;B Nonnenmacher

  • Comprehensive control of human papillomavirus infections and related diseases.

    F. Xavier Bosch;Thomas R. Broker;David Forman;Anna Barbara Moscicki

  • Prophylactic human papillomavirus vaccines

    Douglas R. Lowy;John T. Schiller

  • Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

    Jeffrey N Roberts;Christopher B Buck;Cynthia D Thompson;Rhonda Kines

  • Carrageenan Is a Potent Inhibitor of Papillomavirus Infection

    Christopher B Buck;Cynthia D Thompson;Jeffrey N Roberts;Martin Müller

  • Efficient Intracellular Assembly of Papillomaviral Vectors

    Christopher B. Buck;Diana V. Pastrana;Douglas R. Lowy;John T. Schiller

  • Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

    Rolando Herrero;Wim Quint;Allan Hildesheim;Paula Gonzalez

  • Bovine papillomavirus E2 trans -activating gene product binds to specific sites in papillomavirus DNA

    Elliot J. Androphy;Douglas R. Lowy;John T. Schiller

  • Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

    Heather L. Greenstone;John D. Nieland;Karin E. de Visser;Marloes L. H. De Bruijn

  • Arrangement of L2 within the Papillomavirus Capsid

    Christopher B. Buck;Naiqian Cheng;Cynthia D. Thompson;Douglas R. Lowy

  • Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.

    Rebecca M. Richards;Douglas R. Lowy;John T. Schiller;Patricia M. Day

  • A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

    Reinhard Kirnbauer;Nancy L. Hubbert;Cosette M. Wheeler;Thomas M. Becker

  • Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18

    Diana V. Pastrana;Christopher B. Buck;Yuk Ying S. Pang;Cynthia D. Thompson

  • Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection

    Allan Hildesheim;Rolando Herrero;Sholom Wacholder;Ana C. Rodriguez

Frequent Co-Authors

Douglas R. Lowy
Douglas R. Lowy National Institutes of Health
Allan Hildesheim
Allan Hildesheim National Institutes of Health
Joakim Dillner
Joakim Dillner Karolinska University Hospital
Rolando Herrero
Rolando Herrero Costa Rican Agency for Biomedical Research, INCIENSA Foundation
Richard B.S. Roden
Richard B.S. Roden Johns Hopkins University
Mark Schiffman
Mark Schiffman National Institutes of Health
Reinhard Kirnbauer
Reinhard Kirnbauer Medical University of Vienna
Christopher B. Buck
Christopher B. Buck National Institutes of Health
Ligia A. Pinto
Ligia A. Pinto Leidos (United States)
Sholom Wacholder
Sholom Wacholder National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise after studying Immunology in the USA, pursuing advanced nursing roles can be a rewarding option. Many professionals consider enrolling in cheapest pmhnp programs to specialize in psychiatric mental health, combining immunological knowledge with mental health care.

It’s also important to understand earning potential. For instance, the how much does a dnp make resource offers valuable insights into Doctor of Nursing Practice salaries across different states, helping graduates make informed career decisions.

Additionally, if you are a Family Nurse Practitioner, exploring an fnp to acute care np bridge program can facilitate career growth by enabling a seamless transition to acute care settings, where immunological expertise is highly relevant.

Finally, those seeking to fast-track their nursing credentials should consider accelerated nurse practitioner programs, which provide flexible and intensive pathways to enter advanced practice nursing aligned with immunology.

Best Scientists Citing John T. Schiller

Trending Scientists

Recently Published Articles